Evaluating the effects of the novel GLP1 analogue, Liraglutide, in patients with Alzheimer's Disease (ELAD study): a randomised, double-blind, placebo-controlled trial.
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms ELAD
- 30 Sep 2016 Planned End Date changed from 1 Jan 2017 to 1 Mar 2019.
- 30 Sep 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Mar 2019.
- 28 Jan 2016 Accrual to date is 48% according to United Kingdom Clinical Research Network record.